Guadecitabine (SGI-110): an investigational drug for the treatment of myelodysplastic syndrome and acute myeloid leukemia
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Guadecitabine (SGI-110): an investigational drug for the treatment of myelodysplastic syndrome and acute myeloid leukemia
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume -, Issue -, Pages 1-15
Publisher
Informa UK Limited
Online
2019-09-12
DOI
10.1080/13543784.2019.1667331
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
- (2019) Detlef Haase et al. LEUKEMIA
- Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
- (2019) Andrew H. Wei et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure
- (2019) Marie Sébert et al. HAEMATOLOGICA
- FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation
- (2019) Kelly J. Norsworthy et al. CLINICAL CANCER RESEARCH
- 10-day vs 5-day decitabine: equivalence cannot be concluded
- (2019) Gerwin Huls et al. Lancet Haematology
- 10-day vs 5-day decitabine: equivalence cannot be concluded – Authors' reply
- (2019) Nicholas J Short et al. Lancet Haematology
- Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia
- (2019) Woonbok Chung et al. Clinical Epigenetics
- Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial
- (2019) Guillermo Garcia-Manero et al. Lancet Haematology
- Single-cell exomes in an index case of amp1q21 multiple myeloma reveal more diverse mutanomes than the whole population
- (2018) Dean Bryant et al. BLOOD
- Azacitidine in the ‘real-world’: an evaluation of 1101 higher-risk myelodysplastic syndrome/low blast count acute myeloid leukaemia patients in Ontario, Canada
- (2018) Lee Mozessohn et al. BRITISH JOURNAL OF HAEMATOLOGY
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Systematic Literature Review of Treatment Options and Clinical Outcomes for Patients With Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
- (2018) Jill A. Bell et al. Clinical Lymphoma Myeloma & Leukemia
- Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts
- (2018) Ayalew Tefferi et al. LEUKEMIA
- Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia
- (2018) Prajwal Boddu et al. LEUKEMIA & LYMPHOMA
- Decitabine in Combination with Donor Lymphocyte Infusions can Induce Remissions in relapsed Myeloid Malignancies with Higher Leukemic Burden after Allogeneic Hematopoietic Cell Transplantation
- (2018) Sebastian Sommer et al. LEUKEMIA RESEARCH
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
- (2018) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer immune therapy for myeloid malignancies: present and future
- (2018) Morten Orebo Holmström et al. Seminars in Immunopathology
- DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer
- (2018) Na Luo et al. Nature Communications
- Efficacy of azacitidine is independent of molecular and clinical characteristics-an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature
- (2018) Andrea Kuendgen et al. Oncotarget
- Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents
- (2018) Matthieu Duchmann et al. EBioMedicine
- Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
- (2018) Courtney D. DiNardo et al. BLOOD
- Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
- (2018) Jorge E. Cortes et al. LEUKEMIA
- Classification and Personalized Prognosis in Myeloproliferative Neoplasms
- (2018) Jacob Grinfeld et al. NEW ENGLAND JOURNAL OF MEDICINE
- FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin‐Containing Chemotherapy
- (2018) Daniel L. Suzman et al. ONCOLOGIST
- Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study
- (2018) Naval Daver et al. Cancer Discovery
- Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial
- (2018) Nicholas J Short et al. Lancet Haematology
- Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial
- (2017) Hagop M Kantarjian et al. LANCET ONCOLOGY
- Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes
- (2017) M. Teresa Cedena et al. Oncotarget
- TP53mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes
- (2016) Chun-Kang Chang et al. BRITISH JOURNAL OF HAEMATOLOGY
- TP53mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes
- (2016) Tapan M. Kadia et al. CANCER
- Isocitrate dehydrogenase mutations in myeloid malignancies
- (2016) B C Medeiros et al. LEUKEMIA
- TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
- (2016) John S. Welch et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic Classification and Prognosis in Acute Myeloid Leukemia
- (2016) Elli Papaemmanuil et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
- (2016) Koichi Takahashi et al. Oncotarget
- Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome
- (2016) Seung-Hyun Jung et al. Oncotarget
- Fitness in the elderly: how to make decisions regarding acute myeloid leukemia induction
- (2016) A. V. Rao Hematology-American Society of Hematology Education Program
- Transplantation for myelodysplastic syndromes: who, when, and which conditioning regimens
- (2016) W. Saber et al. Hematology-American Society of Hematology Education Program
- Treatment of Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Stem Cell Transplantation with Azacitidine and Donor Lymphocyte Infusions—A Retrospective Multicenter Analysis from the German Cooperative Transplant Study Group
- (2015) Thomas Schroeder et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
- (2015) H. Dombret et al. BLOOD
- 5-Azacytidine and DLI can induce long-term remissions in AML patients relapsed after allograft
- (2015) J Steinmann et al. BONE MARROW TRANSPLANTATION
- Improving cancer immunotherapy with DNA methyltransferase inhibitors
- (2015) Mohammad H. Saleh et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia
- (2015) Kristen Meldi et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study
- (2015) Jean-Pierre J Issa et al. LANCET ONCOLOGY
- Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes
- (2015) D A Sallman et al. LEUKEMIA
- Molecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidine
- (2015) J Desoutter et al. LEUKEMIA
- Azacytidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN
- (2015) Alessandro Andriani et al. LEUKEMIA RESEARCH
- Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure
- (2015) Stéphanie Harel et al. LEUKEMIA RESEARCH
- Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase
- (2015) Talha Badar et al. LEUKEMIA RESEARCH
- TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
- (2014) R. Bejar et al. BLOOD
- Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts
- (2014) Pragya Srivastava et al. LEUKEMIA RESEARCH
- Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine
- (2014) Cecile Bally et al. LEUKEMIA RESEARCH
- Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms
- (2014) Raajit Rampal et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms
- (2013) J. A. Kennedy et al. BLOOD
- TP53mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis
- (2013) Austin G. Kulasekararaj et al. BRITISH JOURNAL OF HAEMATOLOGY
- Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms
- (2013) F Traina et al. LEUKEMIA
- Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
- (2013) H Yang et al. LEUKEMIA
- Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer
- (2013) Christoph Plass et al. NATURE REVIEWS GENETICS
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?
- (2013) M. Levis Hematology-American Society of Hematology Education Program
- Immunomodulatory activity of SGI-110, a 5-aza-2′-deoxycytidine-containing demethylating dinucleotide
- (2012) Sandra Coral et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Mutant p53: one name, many proteins
- (2012) W. A. Freed-Pastor et al. GENES & DEVELOPMENT
- Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- (2012) Hagop M. Kantarjian et al. JOURNAL OF CLINICAL ONCOLOGY
- Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries
- (2011) C. R. Cogle et al. BLOOD
- TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome
- (2011) F. G. Rucker et al. BLOOD
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure
- (2011) Thomas Prébet et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-Term Survival and Late Deaths After Allogeneic Hematopoietic Cell Transplantation
- (2011) John R. Wingard et al. JOURNAL OF CLINICAL ONCOLOGY
- p53 Lesions in Leukemic Transformation
- (2011) Ashot Harutyunyan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM)
- (2010) S. Thepot et al. BLOOD
- Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy
- (2010) Elias Jabbour et al. CANCER
- Therapeutic options for patients with myelofibrosis in blast phase
- (2010) John Mascarenhas et al. LEUKEMIA RESEARCH
- Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
- (2010) W. Blum et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
- (2009) Pierre Fenaux et al. LANCET ONCOLOGY
- Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs
- (2008) D. E. Rollison et al. BLOOD
- Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine
- (2008) Gautam Borthakur et al. LEUKEMIA & LYMPHOMA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now